A new machine learning tool, a form of artificial intelligence (AI), may accurately detect the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) — and may be able to do so even earlier than clinicians can — a new study showed. According to the…
Read more
While a four-month progressive resistance training program improved muscle strength in people with secondary progressive multiple sclerosis (SPMS) in the Netherlands, it did not significantly change their risk of developing cardiovascular disease, a small study showed. Individual cardiovascular risk factors and 10-year risk estimation tools showed no significant changes…
The Patient-Centered Outcomes Research Institute (PCORI) has awarded the Cleveland Clinic $6.7 million to identify optimal treatment strategies for people with relapsing-remitting multiple sclerosis (RRMS). The funds will support the extension study of the multicenter DELIVER-MS (NCT03535298) clinical trial. The study is comparing two MS treatment approaches…
Bionxt Solutions is getting ready to launch a pilot clinical trial to test BNT23001, its sublingual (under-the-tongue) version of cladribine to treat multiple sclerosis (MS). The treatment would be an alternative to Mavenclad, the approved tablet form of cladribine. Bionxt‘s thin-film formulation quickly dissolves under the tongue,…
Intimacy and sexuality among people with multiple sclerosis (MS) will be the focus of this year’s Holistic Health and Wellness Forum for MS, presented by Yoga Moves MS — a U.S. program aiming to improve quality of life for those with neuromuscular conditions — on May 21 in Michigan…
Get regular updates to your inbox.
